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doi:10.1016/j.ejvs.2010.02.003Abstract Objectives: It is a common clinical observation that collateral vessel development is
impaired in diabetic patients with ischaemic vascular diseases. Consequently, alternative
revascularisation strategies in diabetic patients are needed. This study presents the effect and
mechanism of new peptide therapeutic angiogenesis in an ischaemic and diabetic mousemodel.
Design: Streptozocin-injected mice that had undergone hind-limb ischaemia were treated with
angiogenic peptides. Blood flow restoration was calculated by laser Doppler imager and corrob-
orated by histological section. For the mechanism study, endothelial cells were exposed to
hypoxia and high glucose concentrations to study the effect of the peptides on proliferation
and anti-apoptosis.
Results: The peptides significantly restored blood perfusion 21 days after surgery in the diabetic
mice (p< 0.01) by neo-vascularisation, corroborated by an increase in capillary density. In addi-
tion, the peptides induced the proliferation of hypoxic endothelial cells (p< 0.01) and protected
the cells from apoptosis in high glucose cultures.
Conclusions: This is the first approach for treatment of ischaemic vascular disease with peptides
in a diabetic mouse model.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Diabetes is a major risk factor for cardiovascular diseases.1
Diabetic patients present a different pattern of peripheral
arterial occlusive disease compared with non-diabetic
patients, making it difficult to achieve complete9376782; fax: þ972 3 9216979.
c.il (B. Hardy).
ty for Vascular Surgery. Publisherevascularisation.2 The patients suffering from critical limb
ischaemia are at risk for limb loss and for potentially
fatal complications from the progression of gangrene.3
Current therapy includes peripheral bypass grafting andd by Elsevier Ltd. All rights reserved.
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blood flow; however, a substantial number of patients
are not eligible for these treatments.4 Therapeutic
neo-vascularisation may constitute an important way to
salvage tissue from critical ischaemia.5,6 Neo-
vascularisation is impaired in diabetic patients with
ischaemic vascular diseases due to the altered expression
of angiogenic growth factors such as vascular endothelial
growth factor (VEGF) and related mediators.7,8 In the adult,
neo-vascularisation is thought to result from the migration
and proliferation of pre-existing, fully differentiated
endothelial cells.9,10 In vitro studies of endothelial cells
have shown that a high glucose concentration is associated
with inhibition of proliferation and alterations in
cytoarchitecture.11 Previous in vitro studies have confirmed
that the exposure of human endothelial cells to high
glucose induces significant cell death via apoptosis, which is
particularly well known in models of hyperglycaemia injury,
affecting a significant percentage of vascular endothe-
lium.12e15 Taken together, these observations support the
notion that endothelial dysfunction associated with dia-
betes could contribute to the impaired angiogenesis in
cases of tissue ischaemia.16,17 Thus, there is a great need
for alternative neo-vascularisation treatment strategies in
diabetic patients with critical limb ischaemia. We have
identified a peptide (RoY) by screening a combinatory
phage display peptide library on endothelial cells under
hypoxia conditions that has been shown to induce angio-
genesis using a mechanism independent of VEGF.18 We have
also identified, using a database search, a peptide ADo-
Pep1, derived from ADAM15 protein that contains four
amino acids identical to those of RoY.19,20 ADoPep1’s
therapeutic activity on ischaemic tissues in mice has been
demonstrated using a mouse model in which ischaemia was
induced by femoral artery excision in one leg and blood
perfusion was compared with the non-operated leg by
a laser Doppler imager. A single local administration of RoY
or ADoPep1 significantly restored blood perfusion and
alleviated hind-limb ischaemia in mice. Alleviation of
ischaemia was supported by histological examination
demonstrating an increase in the number of capillaries in
the treated leg. These peptides were found to bind GRP78
heat shock protein on endothelial cell membranes and to
trigger proliferation, migration and tube formation of
endothelial cells under hypoxic conditions. Moreover,
ADoPep1 and RoY peptides inhibited hypoxia-induced
apoptosis in endothelial cells.19,20 The present study eval-
uated the effect of RoY and ADoPep1 peptides in the
alleviation of ischaemia in diabetic mouse hind-limb
ischaemia models. This study aims to elucidate the angio-
genic and anti-apoptotic activity in endothelial cells under
hypoxia exposed to high glucose conditions leading to




Female 9-week-old C57BL6/J mice were used to evaluate
the angiogenic activity of peptides in diabetic mice. Thisstudy was approved by the Institutional Animal Care and
Use Committee of Tel Aviv University conforming to the
NIH Guide for the Care and Use of Laboratory Animals.
Diabetes induction
Diabetes was induced in mice by intra-peritoneal injection
of two series of 40 mg kg1 streptozocin (STZ) (Sigma,
Israel), diluted in citrate buffer pH 4.5 for 5 consecutive
days at week 1 and at 4 weeks later. Glucose in the blood
was measured after the second series of STZ injections.
Insulin treatment
Four groups of C57BL mice were treated with 2 U Bovine
Insulin (Sigma, I1882) three times a week in a subcutaneous
injection, for the duration of the experiment.
Peptide synthesis
ADoPep1 and RoY were synthesised by SynPep (SynPep, CA,
USA). High-performance liquid chromatography (HPLC)
purity was more than 97% for each peptide synthesised.
Peptides were dissolved in water, diluted to a concentra-
tion of 1 mg mL1 and stored at 20 C until use.
Ischaemic hind-limb model
Prior to surgery, mice were anaesthetised by intra-
peritoneal injection of 80 mg kg1 ketamine and
16 mg kg1 xylazine. For hind-limb ischaemia, a longitu-
dinal incision was made on the medial side of the right
thigh, parallel to the proximal arteryeveinenerve
complex. The external iliac artery was ligated twice, and
dissected between the two ligatures.19 One day after
surgery, the mice were divided into four groups of dia-
betic mice as follows: group 1 (n Z 35) was injected with
ADoPep1 peptide, group 2 (nZ 17) was injected with RoY,
group 3 (n Z 23) was injected with VEGF (recombinant
VEGF, PrepoTech, Inc., USA) at 0.5 mg per mouse
according to the optimal concentration obtained previ-
ously; and group 4 (control, n Z 21) was injected with
phosphate-buffered saline (PBS). All injections with
0.1 microgram peptide per mouse were performed intra-
muscularly at a site close to the ligation. Diabetic mice
limbs were scanned postoperatively with a laser Doppler
imager (Perimed, Stockholm, Sweden) on days 7, 14 and
21. For perfusion analyses, mice were anaesthetised and
warmed to 37 C before measurement. Quantification of
the perfusion was done by computer-assisted laser
Doppler perfusion imager. The region of interest for
detailed analysis was indicated by a square. The mean
perfusion of each limb was determined, and the ratio
between the ischaemic (right) and the control, non-
operated (left) limb (relative perfusion) was calculated.
Results are expressed as mean perfusion  SE.
Immunohistochemistry
On day 21, six of each group of STZ-injected mice were
sacrificed and the excised limbs were immediately fixed
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Each block was cut transversely into 3-mm-thick sections
in sequential order, and samples of the gastrocnemic
muscle sections were taken from the same areas of the
control and treated mice. Capillary density was assessed
using CD31 antibody (Rat detection kit for anti-mouse
CD31, Biocare Medical, RT517SK). Capillaries were coun-
ted under a microscope in a total of 30 random fields from
different sections. Density was expressed as the mean
number of capillaries per field of view  SE.
Endothelial cell culture
Human umbilical endothelial cells were purchased from
PromoCell (PromoCell, Heildelberg, Germany). Endothelial
cells were cultured in 25 cm2 tissue-culture flasks
containing supplemented endothelial cell growth mediumFigure 1 a. Peptides significantly alleviated hind-limb ischaemi
b. Images of the laser Doppler show the non-operated (left) and op
treated versus PBS control.followed by incubation with 5% CO2 at 37
C. Cells from
passages 3e4 were used for the different experiments.
Cultures were subjected to hypoxic conditions using a gas
mix of 94% nitrogen þ 5% CO2 þ 1% O2 in a hypoxia chamber
(Billups-Rothenberg, CA, USA).
Proliferation of endothelial cells
Proliferation of endothelial cells was measured by [H3]
thymidine incorporation. Cells seeded on 24-well plates
(12,000 cells/well) were first cultured in endothelial cell
growth medium containing either a normal (5.6 mM) or
a high (30 mM) glucose concentration for 24 h that was
replaced by supplement-free endothelial cell basal medium
containing only 5% foetal calf serum (FCS). ADoPep1
peptide was added at 10 ng mL1 in triplicates for 24 h
under hypoxic conditions followed by 48 h under normoxica on day 21 post-operation *(p Z 0.00058) compared to PBS,
erated treated leg (right) at the different days post-operation,
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ments are expressed as the percent increase in thymidine
incorporation in samples with peptides over samples
without peptides  SD.
Peptide binding to endothelial cells (fluorescence-
activated cell sorter analysis)
Endothelial cells were first cultured for 3 days in endothe-
lial cell growth medium containing either a normal or a high
glucose concentration. The medium was replaced by
supplement-free endothelial cell basal medium containing
only 5% FCS. Cells were trypsinised and transferred to
fluorescence-activated cell sorter (FACS) tubes. Rabbit
polyclonal anti-GRP78 antibody (GRP78, 78-kDa glucose-
regulated protein; Santa Cruz Biotechnologies, CA, USA)
was used for staining endothelial cells (1 mg per
100,000 cells) for 2 h on ice followed by rabbit fluorescein
isothiocyanate (FITC) (Jackson ImmunoResearch, CA, USA).
Anti-rabbit-FITC was used as the isotype control. Samples
were analysed using an FACS (FACScan, Beckton Dickinson,
NJ, USA). The experiments were repeated three times using
endothelial cells from different cords in each experiment.
Results are expressed as percentage GRP78 membrane  SD.
Determination of apoptosis (FACS analysis)
For the determination of apoptosis by FACS analysis,
endothelial cells were harvested and stained with AnnexinFigure 2 a. Histology of mean capillary density in sections of mus
compared to control PBS, b. Representative microphotographs from
100 mm.V-FITC kit (Mebcyto Apoptosis kit, MBL, Naka-Ku Nagoya,
Japan), following the manufacturer’s instructions. The
Annexin-V-positive and PI-negative cells were scored as
apoptotic cells. Caspase 3/7 activity was determined in the
cells by FACS analysis using CaspaTag caspase 3/7 in situ
assay kit (Chemicon International, CA, USA) following the
manufacturer’s instructions. Cells were analysed using an
FACS (FACScan Beckton Dickinson, CA, USA).
Statistical analysis
Analysis of variance and the TukeyeKramer Honestly
Significant Difference (HSD) test for multiple comparisons
were used for the statistical analyses. Results were
considered significant at p < 0.05. JMP software (SAS
Institute, NC, USA) was used for data analysis.
Results
Glucose levels in blood
One week after the second STZ inoculation series, C57Bl mice
showed glucose values in blood of>300mgdL1. Blood glucose
levels in mice were 324  27 mg dL1 (nZ 97, p< 0.05).
Alleviation of ischaemia by ADoPep1
To assess the therapeutic effect of a single intramuscular
injection of the ADoPep1 and RoY peptides in comparisoncle samples in treated mice were significantly higher *(p < 0.01)
limbs of PBS, RoY, ADoPep and VEGF treated mice. Scale bars
Figure 3 a. FACS analysis of percent membrane GRP78 on
hypoxic endothelial cells in high compared to normal glucose,
b. Proliferation was measured by [H]3 thymidine uptake on
hypoxic endothelial cell cultures comparing high glucose to
normal glucose. Cells incubated with ADoPep1 showed signifi-
cantly increased proliferation in different glucose conditions
(*p < 0.01).
Peptides Induce Neo-vascularisation in Diabetic Mice 385to VEGF in diabetic mice, we used the mouse hind-limb
ischaemia model, previously described for the evaluation
of the angiogenic activity of these peptides. Fig. 1(a)
summarises the results of serial laser Doppler imager
analyses in four groups of STZ-treated mice. At 0.1 mg per
mouse, ADoPep1 significantly (p Z 0.000580) alleviated
hind-limb ischaemia and restored relative blood perfusion
to normal after 21 days post-operation with values:
0.86  0.02. At 0.1 mg per mouse, RoY induced lower
values (0.81  0.04, p < 0.01) in comparison to PBS
(0.697  0.03). VEGF was unable to significantly restore
blood perfusion (0.761  0.02) in comparison to PBS. The
laser Doppler imager scans, shown in Fig. 1(b), were
obtained on different days post-operation, in diabetic
ischaemic mouse treated with ADoPep1, compared with
PBS.
Histology of ischaemic limb of diabetic mice
treated with peptides
Fig. 2 demonstrates the histological examinations of
ischaemic legs of C57Bl diabetic mice, 3 weeks post-
treatment. Fig. 2(a) presents capillary density (number of
capillaries per field) that was examined by staining with
anti-CD31. Treatment with ADoPep1 and RoY peptides
significantly increased (p < 0.05) the number of capillariesfrom 1.6  0.18 (in control) to 6.5  0.5 (in RoY) and
5.6  0.27 in ADoPep1-treated mice in contrast to VEGF
(2.5  0.22). Fig. 2(b) presents representative sections
photographed with a digital camera at 400 magnification
from the limbs of mice treated with PBS, RoY, ADoPep1,
and VEGF 21 days post-operation. As described above, the
number of capillaries in the peptide-treated mice is
significantly higher than in control mice.
The effect of high glucose exposure on GRP78
membrane expression
To find out whether high glucose conditions affect the
exposure of membrane GRP78 in hypoxic endothelial cells,
we studied the amount of GRP78 using FACS analysis.
Fig. 3(a) summarises three repeated experiments and
demonstrates that there are no significant differences in
GRP78 expression in endothelial cells under hypoxic
conditions cultured either with normal or high concentra-
tions of glucose. Moreover, the addition of ADoPep1 did not
significantly change the percentage of membrane GRP78
either in normal or in high glucose cultures.
The effect of ADoPep1 treatment on high glucose
endothelial-cell culture proliferation
To test whether ADoPep1 enhances endothelial cell prolif-
eration in high glucose concentration cultures, cells were
incubated with or without the addition of 10 ng mL1
ADoPep at normal or high glucose under hypoxic conditions.
Fig. 3(b) shows a significant threefold increase in cell
proliferation under normal glucose concentrations with the
addition of peptide (p < 0.01). In high glucose conditions,
ADoPep1 induced cell proliferation twofold. Cell prolifera-
tion without the addition of peptide in high glucose
conditions decreased threefold compared with normal
glucose cultures (p < 0.01).
The ADoPep peptide inhibited apoptosis in
endothelial cells exposed to high glucose
concentration cultures
Apoptosis was determined by the percentage of Annexin-V-
positive cells and of caspase 3/7 activity. Fig. 4(a) illus-
trates endothelial cells treated with high glucose and sub-
jected to hypoxia for 24 h with values of 76.5  0.35%
Annexin-V-positive cells. Similar results were obtained in
normal glucose cultures of endothelial cells exposed to
hypoxia (76.9  2.9%). ADoPep1 peptide inhibited hypoxia-
induced apoptosis in normal glucose endothelial cells
cultures in 44% (43  0.57% Annexin-V-positive cells) while
in high glucose cultures, ADoPep1 inhibited hypoxia-
induced apoptosis only in 32% (52  0.57% Annexin-V-
positive cells). Fig. 4(b) shows a representative FACS anal-
ysis of Annexin V/PI staining. Fig. 4(c) illustrates the cas-
pase 3/7 activity in endothelial cells at different culture
conditions. Results obtained by FACS analysis in high
glucose conditions demonstrated a 68.06 relative fluores-
cent activity in contrast to normal glucose (48.7). When
ADoPep1 was added, caspase activity was inhibited by 50%
Figure 4 a. FACS analysis of hypoxia-induced apoptosis in different glucose conditions. Inhibition of apoptosis in the presence of
ADoPep1 is presented (*p < 0.01 and **p < 0.05), b. Representative dot plots of FACS analysis of Annexin V/PI for the determination
of apoptosis, c. Representative histogram of FACS analysis of Caspase 3/7 activity.
386 A. Raiter et al.(27.1) in normal glucose cultures in contrast to only 30%
(48.3 relative fluorescent) in high glucose cultures.Discussion
The present study presents the possibility of a new strategy
of therapeutic angiogenesis by novel angiogenic peptides in
diabetes. A model of hind-limb ischaemia in mice injected
with STZ to develop a form of diabetes with features similar
to those of the human type-I was used. STZ injections
induced hyperglycaemia, as evidenced by the blood glucose
measurement that caused a significant reduction in the
ischaemic hind-limb blood perfusion and in some mice of
the non-ischaemic limb group, compared with healthy mice
(data not shown). In previous reports and in this study,
VEGF, which significantly improved the normal rate of
restoring the blood flow to an ischaemic limb in normal
animals,21,22 failed to enhance the blood flow in ischaemic
limbs of diabetic animals.23 Conversely, other reports
demonstrated that angiogenic therapy with VEGF results in
an amelioration of blood flow in diabetic animals.24 In our
study, significant results were obtained with RoY and ADo-
Pep1 peptides in comparison to PBS- and VEGF-injecteddiabetic mice, supported by previous reports.19,20,22
Histological examinations confirmed neo-vascularisation in
the treated diabetic mice. To understand the mechanism by
which the peptides succeed in restoring the blood flow in
diabetic mice, we exposed endothelial cells to high glucose
and hypoxia conditions and evaluated the percentage of
endothelial cells expressing the membrane GRP78. As
described, RoY and ADoPep1 peptides enclose a common
motif of four amino acids (HWRR) that bind to GRP78 in
endothelial cells membranes19,20 and it is known that
GRP78 expression and presence on surface membranes
increases under conditions of stress such as oxidative
stress, ischaemia and hypoxia.25,26 However, in this study,
we demonstrated that the percentage of the membrane
GRP78 in hypoxic endothelial cells exposed to high glucose
did not change compared with normal glucose concentra-
tions, even in the presence of the peptide. This finding is
contrary to reports related to VEGF expression at mRNA and
protein levels that were significantly reduced at high glucose
conditions.17 On the contrary, hypoxic endothelial cell
proliferation in high glucose cell cultures was significantly
lower than in normal glucose, according to earlier publica-
tions describing that high glucose concentration delayed cell
replication.12 Surprisingly, ADoPep1 induced significant cell
Peptides Induce Neo-vascularisation in Diabetic Mice 387proliferation in high glucose at the same rate as in normal
glucose cultures. Previous studies have established that
exposure of human endothelial cells to high glucose stimu-
lates apoptosis as a result of endothelium tissue damage.17
They have also described the effect of hypoxia-induced
apoptosis of endothelial cells as an important mechanism
of cell death in ischaemic tissues.27,28 In addition, it has
been mentioned that hypoxia affects the expression of
proteins involved in endoplasmic reticulum (ER) stress/
apoptosis such as GRP78 and caspases 3, 7 and 12.29 The
present investigation suggests that hypoxia neutralises the
effect of high glucose in endothelial cell apoptosis. More
than 70% of apoptotic cells were found in cultures exposed
only to hypoxia as well in cultures exposed to either hypoxia
or high glucose conditions. ADoPep1 reduced apoptosis by
44% in normal glucose cultures compared with high glucose
cultures that inhibit only 32% of apoptosis. These results
were confirmed by caspase 3/7 activity reduction that was
lower in high glucose cultures when compared to hypoxia-
induced endothelial cell apoptosis, in the absence of ADo-
Pep1. This is the first approach for the treatment with the
angiogenic peptides of ischaemic vascular disease in dia-
betes. In the mouse model, a single dose of the peptide was
sufficient for a significant blood perfusion restoration.
Binding of the peptide to the receptor triggers extracellular
signal-regulated kinase (ERK) and AKT signal transduction
pathways involved in migration and proliferation of endo-
thelial cells20 causing the growth of new capillaries. For
future clinical applications that might require several
administrations of the peptide, the use of viral vector-
delivering peptide could be applied for a continuous
effect. Taking into account the complications of high glucose
in endothelial cell angiogenesis, the induction of angiogen-
esis and anti-apoptosis by ADoPep1 peptide through GRP78
membrane binding on endothelial cells achieved in this study
gives hope of an alternative treatment approach in diabetic
patients with critical limb ischaemia.
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